95 related articles for article (PubMed ID: 16312180)
1. Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Fuster D; Huertas JA; Gómez G; Solà R; González García J; Vilaró J; Pedrol E; Force L; Tor J; Sirera G; Videla S; Planas R; Clotet B; Tural C;
Antivir Ther; 2005; 10(7):841-7. PubMed ID: 16312180
[TBL] [Abstract][Full Text] [Related]
2. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients.
Mira JA; López-Cortés LF; Merino D; Arizcorreta-Yarza A; Rivero A; Collado A; Ríos-Villegas MJ; González-Serrano M; Torres-Tortoso M; Macías J; Valera-Bestard B; Fernández-Fuertes E; Girón-González JA; Lozano F; Pineda JA;
Antivir Ther; 2007; 12(8):1225-35. PubMed ID: 18240862
[TBL] [Abstract][Full Text] [Related]
3. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin.
Núñez M; Ocampo A; Aguirrebengoa K; Cervantes M; Pascual A; Echeverria S; Asensi V; Barreiro P; Garcia-Samaniego J; Soriano V;
J Viral Hepat; 2008 May; 15(5):363-9. PubMed ID: 18179454
[TBL] [Abstract][Full Text] [Related]
4. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M;
Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555
[TBL] [Abstract][Full Text] [Related]
5. Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin.
Pau AK; McLaughlin MM; Hu Z; Agyemang AF; Polis MA; Kottilil S
AIDS Patient Care STDS; 2006 Sep; 20(9):612-9. PubMed ID: 16987047
[TBL] [Abstract][Full Text] [Related]
6. Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
Bani-Sadr F; Lapidus N; Melchior JC; Ravaux I; Bensalem M; Rosa I; Cacoub P; Pol S; Perronne C; Carrat F
J Viral Hepat; 2008 Apr; 15(4):255-60. PubMed ID: 18307589
[TBL] [Abstract][Full Text] [Related]
7. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
[TBL] [Abstract][Full Text] [Related]
8. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
[TBL] [Abstract][Full Text] [Related]
9. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis.
Shire NJ; Welge JA; Sherman KE
J Viral Hepat; 2007 Apr; 14(4):239-48. PubMed ID: 17381715
[TBL] [Abstract][Full Text] [Related]
10. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
[TBL] [Abstract][Full Text] [Related]
11. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV.
Dominguez S; Ghosn J; Cassard B; Melica G; Poizot-Martin I; Solas C; Lascaux AS; Bouvier-Alias M; Katlama C; Lévy Y; Peytavin G
J Antimicrob Chemother; 2012 Jun; 67(6):1449-52. PubMed ID: 22396433
[TBL] [Abstract][Full Text] [Related]
12. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
[TBL] [Abstract][Full Text] [Related]
13. The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin.
Butt AA; Umbleja T; Andersen JW; Chung RT; Sherman KE;
Aliment Pharmacol Ther; 2011 Jun; 33(11):1234-44. PubMed ID: 21535051
[TBL] [Abstract][Full Text] [Related]
14. Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
Castells L; Esteban JI; Bilbao I; Vargas V; Allende H; Ribera E; Piron M; Sauleda S; Len O; Pahissa A; Esteban R; Guardia J; Margarit C
Antivir Ther; 2006; 11(8):1061-70. PubMed ID: 17302376
[TBL] [Abstract][Full Text] [Related]
15. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects.
Behler CM; Vittinghoff E; Lin F; Chung RT; Peters MG; Robbins GK; Volberding PA
Clin Infect Dis; 2007 May; 44(10):1375-83. PubMed ID: 17443478
[TBL] [Abstract][Full Text] [Related]
16. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the Veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program Office.
Tien PC; ;
Am J Gastroenterol; 2005 Oct; 100(10):2338-54. PubMed ID: 16181388
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin.
Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR
Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903
[TBL] [Abstract][Full Text] [Related]
19. Incident severe thrombocytopenia in veterans treated with pegylated interferon plus ribavirin for chronic hepatitis C infection.
Hermos JA; Quach L; Gagnon DR; Weber HC; Altincatal A; Cho K; Lawler EV; Grotzinger KM
Pharmacoepidemiol Drug Saf; 2014 May; 23(5):480-8. PubMed ID: 24677630
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients.
Crespo M; Sauleda S; Esteban JI; Juarez A; Ribera E; Andreu AL; Falco V; Quer J; Ocaña I; Ruiz I; Buti M; Pahissa A; Esteban R; Guardia J
J Viral Hepat; 2007 Apr; 14(4):228-38. PubMed ID: 17381714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
